Dear Tesla Stock Fans, Mark Your Calendars for September 30
In this article, we'll explore what the Sept. 30 deadline means for Tesla, how it could reshape U.S. EV demand, and why investors should mark their calendars for what may be one of the most pivotal dates for TSLA stock in 2025.
More News from Barchart
Warren Buffett Warns Investing At 'Too-High Purchase Price' Even for 'an Excellent Company' Can Undo a Decade of Smart Investing
Why Archer Aviation's (ACHR) Post-Earnings Tailspin Looks Like a Favorably Mispriced Opportunity
BitMine Immersion Now Holds 1.15 Million Ethereum Tokens. Should You Buy BMNR Stock Here?
Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines.
About Tesla Stock
Tesla is a prominent innovator dedicated to accelerating the global transition to sustainable energy. The Elon Musk-led powerhouse designs, develops, manufactures, leases, and sells high-performance fully electric vehicles, solar energy generation systems, and energy storage products. It also offers maintenance, installation, operation, charging, insurance, financial, and various other services related to its products. In addition, the company is increasingly focusing on products and services centered around AI, robotics, and automation. TSLA's market cap currently stands at $1.1 trillion.
Switch Auto Insurance and Save Today!
The Insurance Savings You Expect
Affordable Auto Insurance, Customized for You
Great Rates and Award-Winning Service
Shares of the EV maker have dropped 15.8% on a year-to-date basis. Tesla shares have been on a steady upward trend since Aug. 5. Several factors have supported the stock's gains. First of all, there's risk-on sentiment across markets, driven by Federal Reserve rate-cut expectations, easing global trade tensions, and a strong Q2 earnings season in the U.S. U.S. EV demand also appears strong in the third quarter, though this is likely driven by the impending loss of the $7,500 federal tax credit in September.
Tesla Rides Sales Surge Ahead of Tax Credit Expiration
The third-quarter EV buying frenzy is underway. The main reason is that consumers are rushing to purchase EVs ahead of a looming deadline to claim tax credits of up to $7,500. As a reminder, U.S. President Donald Trump's 'One Big Beautiful Bill Act,' signed in July, eliminates the tax credits for new, used, and leased EVs after Sept. 30.
The tax credits, worth up to $7,500 for new EVs and $4,000 for used ones, are designed to make EV purchases more financially appealing to consumers. The EV tax incentives were among several policies implemented by the Biden administration to help reduce U.S. greenhouse gas emissions, with the transportation sector being the nation's largest emitter. Notably, under the Biden-era Inflation Reduction Act, the tax credits were initially set to be available to consumers through 2032.
'We're expecting Q3 may be [a] record for EV sales because of the tax incentives going away,' said Stephanie Valdez Streaty, a senior analyst at Cox Automotive. The firm's data revealed that consumers bought nearly 130,100 new EVs in July, marking the second-highest monthly sales on record, trailing only roughly 136,000 sold in December. Streaty said that July's figures represent a 26.4% jump from June and an increase of nearly 20% compared to the same month last year. In addition, EVs made up roughly 9.1% of total passenger vehicle sales in July, the highest monthly share on record. All of this indicates that the impending expiration of the federal tax credit is fueling a surge in demand this quarter.
Analysts noted that dealers are leveraging the upcoming deadline to create a sense of urgency among consumers and drive sales. Tesla's homepage now displays the message '$7,500 Federal Tax Credit Ending' in bold lettering. Beneath it, the automaker added, 'Limited Inventory — Take Delivery Now.'
Meanwhile, Tesla CFO Vaibhav Taneja stated during the Q2 earnings call that the company is prioritizing building and delivering as many vehicles as possible in the U.S. before the tax credits expire. The company has recently extended the estimated wait time for its best-selling Model Y to four to six weeks, up from the previous one-to-three-week range. It's an indication of increased order activity.
On the back of higher U.S. demand, Wall Street projects Tesla will deliver 430,000 vehicles globally in the third quarter. That represents an increase from the 384,000 vehicles delivered in the second quarter but remains below the 463,000 sold in Q3 2024.
How Could EV Tax Credit Elimination Impact Tesla?
The federal electric vehicle tax credit program has played a major role in boosting Tesla's U.S. sales. With the expiration of these credits approaching, Tesla could soon be selling vehicles at effectively higher prices for consumers. And this applies not only to Tesla, but also to other automakers selling EVs, with analysts warning it could trigger a sharp drop in U.S. EV sales in the fourth quarter and beyond. Notably, there are already precedents for how similar policy changes have impacted EV adoption, as seen in Germany, where EV sales dropped sharply following the end of subsidies in late 2023. So, the first obvious implication is a decline in consumer demand.
Of course, automakers could lower prices to help offset the loss of tax subsidies. For instance, Ford (F) cut prices on its Mustang Mach-E after it lost a $3,750 tax credit in January 2024, while General Motors (GM) provided a $7,500 incentive on models that lost the credits at that time. In Tesla's case, this would impact its unit gross profits, as average vehicle selling prices would have to drop substantially to offset the loss of the EV tax credit. And this comes at a time when its average selling prices have already been under pressure in recent quarters due to intense competition.
With that, regardless of Tesla's response, the elimination of EV tax credits represents a significant headwind for the company. Tesla CEO Elon Musk, during the Q2 earnings call, warned of tough times ahead for the company as incentives such as the EV tax credit phase out in the U.S. 'We probably could have a few rough quarters,' Musk said.
Meanwhile, the company is expected to launch its more affordable vehicle, which Musk described as resembling a Model Y, to the public in the fourth quarter. On the one hand, the vehicle is likely to provide some support to delivery volumes. On the other hand, the affordable model could cannibalize Model Y sales since it is essentially a stripped-down version of the latter. With that, monitoring delivery figures will be key to assessing the potential impact of cannibalization. Anyway, I expect a decline in deliveries, both sequentially and year-over-year, in Q4.
Over the past few months, analysts have gradually reduced their estimates for Tesla's fourth-quarter top and bottom lines. They currently expect Tesla's adjusted EPS for Q4 to fall 45.5% year-over-year to $0.36, while revenue is projected to remain largely unchanged at $25.81 billion.
What Do Analysts Expect for TSLA Stock?
Wall Street analysts remain split on Tesla, with the stock carrying a consensus 'Hold' rating. Among the 41 analysts covering the stock, 12 rate it as a 'Strong Buy,' two as a 'Moderate Buy,' 17 recommend holding, and 10 assign a 'Strong Sell' rating. TSLA stock is currently trading above its average price target of $299.28.
On the date of publication, Oleksandr Pylypenko did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Omeros Corp (OMER) Q1 2025 Earnings Call Highlights: Strategic Debt Reduction and Narsoplimab ...
Net Loss: $33.5 million or $0.58 per share for Q1 2025, compared to $31.4 million or $0.54 per share in Q4 2024. Cash and Investments: $52.5 million as of March 31, 2025. Debt Reduction: Total debt reduced by $10 million, with near-term repayment obligations lowered from $118 million to $17 million. OMIDRIA Royalties: $6.7 million for Q1 2025 based on net sales of $22.3 million, down from $10.1 million in Q4 2024. Interest Expense: $3.7 million for Q1 2025, reflecting a $477,000 increase from Q4 2024. Operating Expenses: $35 million for Q1 2025, a decrease of $691,000 from Q4 2024. Income from Discontinued Operations: $4.1 million for Q1 2025, down $1.1 million from Q4 2024. Warning! GuruFocus has detected 2 Warning Signs with OMER. Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Omeros Corp (NASDAQ:OMER) has successfully negotiated an exchange agreement to extend the maturity of its convertible notes from 2026 to 2029, reducing near-term debt obligations by over $100 million. The company has an active at-the-market facility with the capacity to raise up to $150 million, providing flexibility to access additional capital. The FDA has accepted the resubmitted Biologics License Application for narsoplimab in TA-TMA, with a target action date set for September 25. Omeros Corp (NASDAQ:OMER) is well-prepared for the potential launch of narsoplimab, having identified key transplant centers and engaged with payers to ensure patient access. The company is advancing its pipeline with ongoing clinical trials for zaltenibart in PNH and OMS527 for cocaine use disorder, supported by a grant from the National Institute on Drug Abuse. Negative Points Omeros Corp (NASDAQ:OMER) reported a net loss of $33.5 million for the first quarter of 2025, an increase from the previous quarter. The company has suspended its Expanded Access Program for narsoplimab, affecting patients who lack approved treatment options for TA-TMA. There is a temporary pause on the Phase 3 program for zaltenibart in PNH due to capital considerations, potentially delaying its development timeline. OMIDRIA royalties decreased significantly in the first quarter of 2025 compared to the previous quarter, impacting revenue. Interest expense increased in the first quarter, driven by changes in the OMIDRIA royalty obligation and new convertible notes. Q & A Highlights Q: Can you provide details on the launch plans for narsoplimab and its impact on patient access? A: Greg Demopulos, Chairman & CEO, stated that the company is well-prepared for the launch, expecting it to be successful. Nadia Dac, Chief Commercial Officer, elaborated that the team is focused on the top 40 transplant centers responsible for 60% of the allogeneic transplant volume. They have identified key decision-makers and are engaging with payers, emphasizing narsoplimab's unique value as the only approved treatment for TA-TMA. Q: Can you provide more information about the patients affected by TA-TMA and the associated healthcare costs? A: Greg Demopulos explained that TA-TMA is an unpredictable complication of stem cell transplants, often resulting in rapid deterioration and high mortality. Nadia Dac added that untreated patients incur significant costs, such as ICU stays and organ failure treatments. Narsoplimab aims to reduce these costs by offering an effective outpatient treatment option. Q: How are you managing the financial aspects of the company, particularly regarding debt and capital raising? A: Greg Demopulos highlighted the recent exchange agreement that reduced the 2026 convertible notes' principal, lowering near-term repayment obligations by over $100 million. The company is also exploring partnerships for non-dilutive funding and has an active at-the-market facility to raise up to $150 million. Q: What are the strategic priorities for Omeros beyond narsoplimab? A: Greg Demopulos mentioned that the company is prioritizing the development of zaltenibart for paroxysmal nocturnal hemoglobinuria (PNH) and continuing its PDE7 inhibitor program for cocaine use disorder, funded by a NIDA grant. They are also advancing their oncology platform, Oncotox, targeting acute myeloid leukemia. Q: What is the current status of the narsoplimab BLA resubmission and its potential market impact? A: Greg Demopulos confirmed that the FDA has accepted the resubmitted BLA for narsoplimab in TA-TMA, with a target action date of September 25. The company anticipates narsoplimab to be the first approved therapy for TA-TMA, addressing a nearly $1 billion annual market opportunity. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
11 minutes ago
- Yahoo
Beeline Holdings Inc (BLNE) Q2 2025 Earnings Call Highlights: Strategic Divestment and Revenue ...
Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Beeline Holdings Inc (NASDAQ:BLNE) successfully divested its spirits assets, allowing a full focus on its core digital mortgage lending business. The company reported a 27% increase in revenue and a 40% decrease in expenses in Q2 2025 compared to Q1 2025. Beeline Holdings Inc (NASDAQ:BLNE) introduced a new equity product that is not tied to interest rates, providing a competitive advantage. The AI sales agent, Bob, significantly improved lead conversion and mortgage application rates, contributing approximately $150,000 in revenue. The company reduced its debt by $6.2 million in 2025, aiming to be debt-free by November 1, 2025, and cash flow positive by January 2026. Negative Points The market remains challenging due to higher interest rates affecting refinance and purchase transactions. The company reported a net loss from continuing operations of $4 million for Q2 2025. There were $500,000 in one-time non-recurring expenses in Q2, impacting financial results. The broader launch of the new equity product has been delayed to ensure proper execution and customer satisfaction. Despite improvements, the company still faces significant scaling challenges and uncertainties in its new product offerings. Q & A Highlights Warning! GuruFocus has detected 5 Warning Signs with BLNE. Q: Can you provide more details about the home equity cash-out product and the timing of its broader launch? A: (Nick Lauza, CEO) We initially planned to launch in late August or early September but decided to delay to ensure we get it right. The opportunity is massive, with untapped equity in the US market. The Genius Act provides regulatory clarity, and we want to ensure the product is perfect before scaling. We will conduct a select number of transactions over the next 30 to 45 days to gather feedback and ensure consumer interests are prioritized. Q: What are the assumptions behind your profitability projections for late this year or early next year? A: (Nick Lauza, CEO) We are focusing on achieving profitability quickly by cutting $225,000 in monthly recurring expenses, which will be fully realized by September. Our locks are up, and we've reduced our marketing budget by $40,000 monthly while maintaining strong performance. We also had $500,000 in one-time expenses in Q2, which won't recur. We aim to be debt-free by November 1 and cash flow positive by January 2026. Q: Can you explain the economics of the fractional products and the expected volume at scale? A: (Nick Lauza, CEO) Our margins will be higher than our mortgage products, with less work involved since we're underwriting the property, not the consumer. We expect about 33% more revenue per file. Marketing expenses will be minimal as our partner will drive the business. We've identified about 1,000 potential customers who would qualify for this product. Q: What will drive significant growth in 2026, even without rate cuts? A: (Nick Lauza, CEO) We expect strong demand for Beeline Equity, as it provides liquidity based on home equity rather than individual qualifications. This product is ideal for those who can't qualify for cash-out refis or HELOCs. Additionally, our mortgage business is improving, and we have a strong title business team. We anticipate the equity product to be our largest revenue generator in 2026, followed by the mortgage and title businesses. Q: Do you have a sensitivity analysis for how rate cuts could impact growth? A: (Nick Lauza, CEO) While we don't have specific figures, a 25 basis point cut would significantly impact our business as a centralized digital lender. Digital models perform better in low-rate environments, and a 1-point cut would lead to rapid growth. (Chris Moe, CFO) Additionally, the longer rates remain high, the more significant the impact of a cut due to pent-up demand. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
11 minutes ago
- Yahoo
Dare Bioscience Inc (DARE) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial ...
Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Dare Bioscience Inc (NASDAQ:DARE) is on track to launch its sildenafil cream, Dare to Play, through a 503b outsourcing facility in Q4 2025, marking a significant milestone in women's sexual health. The company is advancing a differentiated clinical pipeline with grant-funded programs targeting unmet needs in contraception, HPV, and preterm birth. Dare Bioscience Inc (NASDAQ:DARE) received positive feedback from its direct-to-patient awareness campaign, highlighting significant interest in its products. The Oviprine Phase 3 trial continues as planned with no new safety concerns, supporting its potential as a hormone-free contraceptive option. The company strengthened its financial position with $17.6 million in net proceeds from stock sales and a $6 million grant payment, enhancing its ability to execute its strategy. Negative Points Dare Bioscience Inc (NASDAQ:DARE) ended the quarter with a working capital deficit of approximately $12.6 million. The company experienced a 71% decrease in R&D expenses compared to Q2 2024, primarily due to reductions in manufacturing and development costs. There were technical difficulties during the earnings call, preventing a Q&A session, which may have limited investor engagement. The company's dual path strategy involves risks associated with FDA approval processes and market acceptance of its products. Despite the progress, the company operates in a highly competitive market with significant challenges in bringing new women's health solutions to market. Q & A Highlights Warning! GuruFocus has detected 3 Warning Signs with DARE. Q: What is the status of the Dare to Play Sildenafil Cream launch? A: Sabrina Martucci Johnson, President and CEO, stated that Dare Bioscience remains on track to support the commercial availability of Dare to Play Sildenafil Cream through a 503b outsourcing facility in the fourth quarter of 2025. This launch is a significant milestone for the company and the field of women's sexual health. Q: Can you provide an update on the Ovaprine Phase 3 trial? A: Sabrina Martucci Johnson explained that the Independent Data and Safety Monitoring Board reviewed interim data from the Phase 3 study and recommended that the trial continue as planned. The interim pregnancy rate was consistent with expectations, supporting Ovaprine's potential as a non-hormonal contraceptive option. Q: What is the dual commercialization pathway for DARE HRT1? A: Sabrina Martucci Johnson highlighted that DARE HRT1, an intravaginal ring for hormone therapy, is pursuing both FDA approval and a 503b compounding opportunity. This approach aims to accelerate patient access while generating necessary data for FDA approval. Q: How is Dare Bioscience expanding into consumer health products? A: Sabrina Martucci Johnson announced plans to launch two non-prescription vaginal probiotics to support vaginal microbiome health. These products will complement the prescription offerings and diversify the company's commercial platform. Q: What are the financial highlights for the second quarter of 2025? A: Marty Herringlayton, Chief Accounting Officer, reported that Dare Bioscience ended the quarter with approximately $5 million in cash and a working capital deficit of $12.6 million. Post-quarter, the company received $17.6 million from stock sales and a $6 million grant, strengthening its balance sheet. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data